American Journal of Gastroenterology最新文献

{"title":"Continuing Medical Education Questions: September 2026.","authors":"Kanwarpreet S Tandon","doi":"10.14309/ajg.0000000000004160","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004160","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":"121 9","pages":"2084"},"PeriodicalIF":8.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACG Workforce of the Future Task Force: The Anesthetizing Task Force Report.","authors":"Dayna Early, Stephen T Amann, Brooks Cash, Daniel Pambianco, Shabana F Pasha, Sheetal Sharma, Amy Stratton, And John Vargo","doi":"10.14309/ajg.0000000000004108","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004108","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":"121 9S","pages":"S17-S29"},"PeriodicalIF":8.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACG Clinical Guideline: Diagnosis and Management of Adenomatous Colorectal Polyposis Syndromes.","authors":"Gautam Mankaney, Gregory E Idos, Elena M Stoffel, Jennifer M Weiss, Shailja Shah, Emad Qayed, Mary Pat Harnegie, Carol A Burke","doi":"10.14309/ajg.0000000000004105","DOIUrl":"10.14309/ajg.0000000000004105","url":null,"abstract":"<p><p>The hereditary adenomatous colorectal polyposis syndromes are incurable, systemic, cancer risk predisposition syndromes with substantial morbidity and mortality. They differ in their mode of inheritance, age at disease onset, phenotypic expression, and cancer risk. The most common cancer risks involve the gastrointestinal tract including the colon, rectum, duodenum, ampulla, and stomach. Identifying these syndromes through personal and family history risk assessment and germline genetic testing, along with timely surgical and endoscopic management, can reduce cancer incidence and mortality. These guidelines use the Grading of Recommendations, Assessment, Development, and Evaluation methodology to provide clinical guidance on the selection of individuals who should undergo a risk assessment for a hereditary adenomatous colorectal polyposis syndrome, modality and timing of germline genetic testing, cancer risk mitigation through endoscopic and surgical interventions, and the role of chemoprevention. This document reviews the approach to genetic testing in patients with phenotypic colorectal polyposis and the impact of presymptomatic diagnosis in families with a known familial germline pathogenic variant or clinical features suggestive of a hereditary adenomatous polyposis syndrome. Management strategies for patients based on genetic test results or without genetic testing are provided. We also review colorectal and extracolonic phenotypic benign and malignant manifestations of the known hereditary syndromes with a focus on the 2 most common hereditary colorectal polyposis syndromes: familial adenomatous polyposis and MUTYH-associated polyposis. The document concludes with recommendations on polyposis and cancer risk mitigation strategies and highlights updates to management since the previous guideline was published.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":"121 9","pages":"2086-2120"},"PeriodicalIF":8.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calendar of Courses, Symposiums and Conferences.","authors":"","doi":"10.14309/ajg.0000000000004162","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004162","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":"121 9","pages":"2355"},"PeriodicalIF":8.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACG Workforce of the Future Task Force: A Multidimensional Assessment of GI Workforce Challenges and Recommendations.","authors":"Amy S Oxentenko, Tauseef Ali, Dayna Early, Neil Stollman, Jean-Paul Achkar, Stephen T Amann, Brooks Cash, Sarah Enslin, Irteza Inayat, Gregory Kantor, Monica Nandwani, Mariam Naveed, Kimberly Orleck, Daniel Pambianco, Shabana F Pasha, K Gautham Reddy, Vonda Reeves, Drew Schembre, Sheetal Sharma, Amy L Stewart, Bria Strada, Amy Stratton, Emeline Suttie, John Vargo, Ronald Vender, Patrick E Young","doi":"10.14309/ajg.0000000000004106","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004106","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":"121 9S","pages":"S1-S3"},"PeriodicalIF":8.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primer: Understanding Medicare for Advanced Therapies for Inflammatory Bowel Disease.","authors":"David Choi, Hilary Sheridan, Tenzin Choden","doi":"10.14309/ajg.0000000000004042","DOIUrl":"10.14309/ajg.0000000000004042","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2068-2072"},"PeriodicalIF":8.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147832278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cendakimab for Eosinophilic Gastritis and Duodenitis in Japanese Adults and Adolescents: Results from a Phase 3 Randomized Controlled Trial.","authors":"Yoshikazu Kinoshita, Shiro Oka, Kayoko Matsushima, Mikinori Kataoka, Tsuyoshi Sanuki, Yasuhiro Fujiwara, Katsuhiro Arai, Shuichi Midorikawa, Hirotsugu Hatai, Christina M Charriez, Sandra Zhang, Jie Li, Keigo Asano, Ichiro Nomura","doi":"10.14309/ajg.0000000000004192","DOIUrl":"10.14309/ajg.0000000000004192","url":null,"abstract":"<p><strong>Introduction: </strong>Eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD; EG/EoD) are rare, chronic inflammatory disorders lacking approved treatments.</p><p><strong>Methods: </strong>We report a randomized, double-blind, placebo-controlled phase 3 trial evaluating cendakimab, an anti-IL-13 monoclonal antibody, in 48 Japanese patients with EG/EoD.</p><p><strong>Results: </strong>At week 16, cendakimab significantly reduced mean peak gastrointestinal eosinophil counts vs placebo (least squares mean difference -223.2 eosinophils/high-power field; P = 0.003), with numerical improvements across symptom domains. Histologic effects were maintained at week 48 and a favorable safety profile was observed.</p><p><strong>Discussion: </strong>These findings highlight IL-13 inhibition as a potential treatment strategy for EG/EoD.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Accuracy of a Capsule Sponge Trefoil Factor 3 Test for Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.","authors":"Eduardo A Canto, Amar K Rai, Stephen J Lostetter, Aditya V Avula, Thomas Round, Ryan W Walters, Aun R Shah, Steven F Moss","doi":"10.14309/ajg.0000000000004190","DOIUrl":"10.14309/ajg.0000000000004190","url":null,"abstract":"<p><strong>Introduction: </strong>Current guidelines suggest swallowable capsule-sponge devices with biomarkers can be used as alternatives to endoscopy for detecting Barrett's Esophagus (BE) in at-risk patients. We analyzed the screening performance of capsule-sponge with trefoil-factor-3 (TFF3) in patients with symptomatic acid reflux and assessed test performance across individual risk factors.</p><p><strong>Methods: </strong>The study protocol was registered in Prospective Register of Systematic Reviews (PROSPERO) (CRD420250652091). Eligible studies reported results for both capsule-sponge-TFF3 and endoscopic assessment in adults with reflux symptoms and no history of BE. A systematic search was conducted through August 29, 2025. Two reviewers independently screened and extracted data using COllaboration + eVIDENCE (COVIDENCE). Risk of bias was assessed by QUality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Sensitivity and specificity were estimated in SAS v9.4 using bivariate mixed models allowing estimation of likelihood ratios, diagnostic odds ratios, and predictive values; meta-regression models were estimated for individual risk factors, acid suppressant use and BE prevalence.</p><p><strong>Results: </strong>We identified 6 studies involving 1,454 participants in our meta-analysis. Pooled sensitivity for BE was 0.87 (95% CI: 0.80-0.94), specificity was 0.88 (95% CI: 0.80-0.95), negative predictive value at 20% prevalence was 0.96 (95% CI: 0.95-0.98), and the diagnostic odds ratio was 47.82 (95% CI: 44.99-50.83). Smoking and acid suppressant use were associated with increased specificity.</p><p><strong>Discussion: </strong>Overall, our findings show that capsule-sponge-TFF3 is an effective minimally invasive screening tool for patients at risk of BE. Increased specificity in smokers may help reduce unnecessary endoscopies in this higher-risk group.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.","authors":"Tetsuji Takayama, Koichi Okamoto, Hideki Ishikawa, Kaizo Kagemoto, Tatsuhisa Yasaka, Takashi Hisabe, Koichi Kawabe, Toyotaka Kasai, Masaya Kubota, Masahito Shimizu, Tomoyuki Abe, Jiro Nakamoto, Masahiko Nakasono, Sho Takahashi, Keita Harada, Shinji Kitamura, Hisashi Nakamura, Shinya Minami, Manabu Sawaya, Koshi Fujikawa, Toshihito Tanahashi, Shin-Ichiro Hori, Tsutomu Nagata, Yasushi Sato, Michihiro Mutoh","doi":"10.14309/ajg.0000000000004193","DOIUrl":"10.14309/ajg.0000000000004193","url":null,"abstract":"<p><strong>Introduction: </strong>Experimental and limited clinical studies suggest that curcumin has chemopreventive activity in the colorectum. This large-scale clinical trial evaluated the efficacy and safety of curcumin in patients with previously endoscopically resected colorectal neoplasia.</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled multicenter trial enrolled patients with previously resected colorectal neoplasia. Eligible patients were randomly assigned (1:1), using a stratified, computer-generated scheme to receive oral submicron-powdered curcumin (Theracurmin; 180 mg twice daily) or identical placebo capsules for 2 years. All analyses were performed according to a modified intention-to-treat principle including all randomly assigned patients who underwent the 2-year colonoscopy.</p><p><strong>Results: </strong>Between April 1, 2016, and March 31, 2020, 577 patients were randomly assigned to curcumin (n = 287) or placebo groups (n = 290). The detection rate of recurrent colorectal adenomas at 2 years, the primary end point, did not differ significantly between groups (risk ratio 0.98; 95% confident interval 0.82-1.16). However, the detection rate of adenomas ≥6 mm, a prespecified lesion category recommended for endoscopic resection in Japanese guidelines, was significantly lower with curcumin (risk ratio, 0.56; 95% confident interval, 0.33-0.95; P = 0.04). The per-patient number of adenomas ≥6 mm was also significantly lower ( P = 0.03), and the median size of all detected adenomas was significantly smaller in the curcumin group ( P = 0.003). The inhibitory effect seemed more pronounced in patients with higher baseline adenoma burden and in men in exploratory analyses. Treatment-related adverse events were infrequent and mild.</p><p><strong>Discussion: </strong>Curcumin inhibited the growth of recurrent colorectal adenomas, despite no significant reduction in the overall incidence of recurrence. This is the first large-scale randomized clinical trial demonstrating the suppressive efficacy of curcumin against colorectal neoplasia, and also highlighting the importance of incorporating growth-related endpoints, in addition to incidence-based or detection-based end points, in chemoprevention studies (jRCTs061180079).</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Greater Esophageal Cancer Burdens in Rural United States: A Surveillance, Epidemiology, and End Results Program Analysis.","authors":"Annabel Gerber, Ji Yoon Yoon, Chin Hur, Joel H Rubenstein","doi":"10.14309/ajg.0000000000004189","DOIUrl":"10.14309/ajg.0000000000004189","url":null,"abstract":"<p><strong>Aim: </strong>To compare rural and urban trends in esophageal cancer (EC) incidence and mortality, including adenocarcinoma (EAC), squamous cell carcinoma (ESCC), and esophagogastric junction adenocarcinoma (EGJAC).</p><p><strong>Methods: </strong>Joinpoint analysis of Surveillance, Epidemiology, and End Results (SEER) registries from 1992 through 2022.</p><p><strong>Results: </strong>EAC incidence and mortality were greater in rural areas, with trends diverging around 1999. EGJAC incidence and mortality and ESCC incidence decreased in urban areas and had no significant trend in rural areas.</p><p><strong>Conclusion: </strong>There are substantial disparities in EC incidence and mortality trends by rurality. Understanding the cause of these trends could support cancer control efforts.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}